CCCaroline de Courville

Caroline de Courville

*This is an algorithmically generated author record based on publicly available information.

Caroline de Courville has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness and public health impact of using high dose influenza vaccine in the Japanese older adults

    by Caroline de Courville, Chiho Tadera, Takeshi Arashiro, Florence Bianic, Mafalda Costa, Mohit Joshi, Xinyu Wang

    High-dose (HD) influenza vaccine, which has demonstrated superior efficacy and acceptable safety compared to standard-dose (SD), has market authorization in many countries. This study evaluated the public-health impact and cost-effectiveness of HD versus SD in Japanese older-adults (OAs) from healthcare payer-perspective. Decision-tree model was employed assessing health outcomes for each vaccination strategy, simulating influenza cases, outpatient/emergency department (ED) visits, hospitalizations, and mortality, over one-year time-horizon. Incremental cost-effectiveness ratios (ICER) were assessed at Japanese willingness-to-pay (WTP) threshold. Base-case analysis considered influenza vaccines effective against influenza hospitalizations only, whereas complementary analyses reflected their efficacies against Pneumonia and Influenza (P&I), respiratory and cardiorespiratory hospitalizations possibly related to influenza among individuals ≥65 years. Scenario analysis extended target population to at-risk individuals aged 60-64 years. Uncertainty was assessed using sensitivity analyses. In base-case, switching from SD to HD prevented 174,863 influenza cases, 121,084 outpatient and 614 ED visits, annually. Further, 5,777 influenza hospitalizations, and 2,406 deaths related to influenza were avoided with HD vaccine. The HD vaccine was found to be a cost-effective strategy at WTP threshold of ¥5,000,000/Quality-Adjusted-Life-Years (QALY) with ICER of ¥4,876,512/(QALY). Sensitivity analyses confirmed the robustness of these findings. Complementary analyses showed notably improved outcomes, in terms of public-health, economic impact, and ICERs, when considering efficacy of influenza vaccines against P&I, respiratory, and cardiorespiratory hospitalizations possibly related to influenza. These results indicate that HD vaccine has a high economic value in Japan compared to SD. Implementing HD vaccine could effectively alleviate the burden on healthcare facilities for Japanese OAs.


  • Open Access

    The Burden of Seasonal Influenza and Its Potential Complications Among Older Japanese Adults: A Real‐World Database Study

    by Takeshi Arashiro, Yuki Tajima, Yohei Ban, Matthew M. Loiacono, Masayo Ideguchi, Caroline de Courville

    Background: Seasonal influenza may lead to severe complications, including respiratory and cardiovascular disease, that result in considerable healthcare resource utilization (HCRU) and mortality, particularly in older individuals. This real‐world study assessed the burden of influenza and its potential complications in older Japanese adults.Methods: This retrospective claims database analysis (April 2015 to June 2019) included insured individuals aged ≥ 60 years at the start of four consecutive influenza seasons in Japan (October 1 to April 30). The primary endpoint was the incidence of influenza‐related emergency room (ER) and outpatient visits, the incidence of hospitalizations, the probability of 30‐day inpatient mortality, and 60‐day medical costs of influenza or its potential complications.Results: Of 8,974,708 individuals (43.2% male, mean ± standard deviation age 73.8 ± 8.9 years), 370,430 (4.13%) were diagnosed with influenza. Overall, 17.18 (95% confidence interval [CI] 16.32–18.04) and 3893.53 (3880.87–3906.19) per 100,000 individuals had influenza‐related ER and outpatient visits, respectively, and 181.50 (178.71–184.28) per 100,000 individuals were hospitalized for influenza. The incidence of influenza‐related ER visits and hospitalizations for influenza or potential complications and the probability of 30‐day inpatient mortality increased with age.Conclusions: Seasonal influenza and its potential complications represent a substantial burden that increases with age in Japanese individuals.


  • Open Access

    Cost-effectiveness and public health impact of using high dose quadrivalent influenza vaccine in the French older adults population

    by F. P. Alvarez, L. Allard, F. Bianic, H. Bricout, P. Crépey, J. Gaillat, G. Gavazzi, A. Mosnier, O. Launay, M. C. Levant, et al.

    Seasonal influenza outbreaks in France cause a surge in patients, exacerbating the overburdened healthcare system each winter. Older adults are particularly vulnerable to serious events related to influenza. Quadrivalent influenza high dose (QIV HD) vaccines have been developed to offer better clinical protection in older adults, who often exhibit suboptimal immune response to quadrivalent influenza standard dose vaccines (QIV SD). This study aims to evaluate the public health impact and cost-effectiveness of administering HD versus SD vaccines to individuals aged 65+ in France. Using a static model and decision-tree approach, the study analyzed health outcomes such as influenza cases, GP (general practitioner) visits, hospitalizations, and mortality; relative vaccine efficacy (rVE) estimates were derived from a pivotal randomized-controlled trial and a meta-analysis comparing HD to SD vaccines. Two approaches were implemented to model hospitalizations (conditional on influenza or not), and analyses on bed occupancy were performed. Results showed that using QIV HD instead of QIV SD during an average influenza season in France led to the prevention of 57,209 additional cases of influenza, 13,704 GP visits, and 764 influenza-related deaths. Moreover, switching to QIV HD resulted in additional 1,728 to 15,970 hospitalizations avoided and 15,124 to 138,367 reduced days of hospitalization depending on the hospitalization approach used. The cost-utility analysis showed a cost per quality-adjusted life year (QALY) gained ranging from 24,020 €/QALY to 5,036 €/QALY. Switching to QIV HD in older adults showed to be cost-effective, with even greater public health benefits at higher coverage rate, regardless the season severity.


  • Open Access

    Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal

    by Fabián P. Alvarez, Pierre Chevalier, Matthias Borms, Hélène Bricout, Catia Marques, Anu Soininen, Tatu Sainio, Christine Petit, Caroline de Courville

    Seasonal influenza may result in severe outcomes, resulting in a significant increase of hospitalizations during the winter. To improve the protection provided by the standard dose influenza quadri...


  • Top Cited Papers
    Open Access

    The economic burden of influenza among adults aged 18 to 64: A systematic literature review

    by Caroline de Courville, Sarah M. Cadarette, Erika Wissinger, Fabián P. Alvarez

    While the economic burden of influenza infection is well described among adults aged 65 and older, less is known about younger adults. A systematic literature review was conducted to describe the economic burden of seasonal influenza in adults aged 18 to 64 years, to identify the main determinants of direct and indirect costs, and to highlight any gaps in the existing published evidence. MEDLINE and Embase were searched from 2007 to February 7, 2020, for studies reporting primary influenza‐related cost data (direct or indirect) or absenteeism data. Of the 2613 publications screened, 51 studies were included in this review. Half of them were conducted in the United States, and 71% of them described patients with influenza‐like illness rather than laboratory‐confirmed disease. Only 12 studies reported cost data specifically for at‐risk populations. Extracted data highlighted that within the 18‐ to 64‐year‐old group, up to 88% of the economic burden of influenza was attributable to indirect costs, and up to 75% of overall direct costs were attributable to hospitalizations. Furthermore, within the 18‐ to 64‐year‐old group, influenza‐related costs increased with age and underlying medical conditions. The reported cost of influenza‐related hospitalizations was found to be up to 2.5 times higher among at‐risk populations compared with not‐at‐risk populations. This review documents the considerable economic impact of influenza among adults aged 18 to 64. In this age group, most of the influenza costs are indirect, which are generally not recognized by decision makers. Future studies should focus on at‐risk subgroups, lab‐confirmed cases, and European countries.